Delivery comparator

Same molecule. Different vehicle. Different outcome.

Standard moisturisers and serums work, but their actives sit on the surface, oxidise and arrive all at once. Entrapping the same molecules in Cetosome® nanovesicles changes where they go, how long they last and how the skin tolerates them.

01 Moisturisers

Normal moisturiser vs. Cetosome® moisturiser

Answer first

A normal moisturiser hydrates by drawing water into the surface and slowing evaporation, and most of its actives stay in the film until wiped or washed away. A Cetosome® moisturiser adds lamellar lipids that resemble the barrier and holds actives in vesicles that release gradually, so benefits outlast the film. Barrier support improves.

Normal moisturiserCetosome® moisturiser
Where it actsSurface film; humectants draw water, occlusives slow lossSurface film plus lamellar lipid structure that integrates with barrier lipids
Active payloadMostly unprotected; oxidises and rubs offHeld in vesicles; shielded from air and light
DurationPeaks at application, fades over hoursGradual release over up to 24 h
Barrier fitDepends on lipid ratios; often non-lamellarCetylated lamellae resemble ceramide–cholesterol–fatty-acid mortar
Best forSimple hydrationBarrier repair with actives (ceramides, niacinamide, urea)

Barrier lipid architecture [3]; molecular size limits for ceramides[2]; vesicle stability and release [4].

02 Serums

Normal serum vs. Cetosome® serum

Answer first

A normal serum dissolves actives in water, alcohol or glycols and releases them at once. That gives the early concentration peak linked to stinging, redness and dryness, followed by a fast decline. A Cetosome® serum keeps most of the active in vesicles and releases it over hours, lowering the peak while holding effective levels longer.

Normal serumCetosome® serum
Free-active peakHigh in the first minutes to an hourLower; spread over hours
Stinging / erythema riskTracks the peak; highest in weeks 1–4Reduced by lower peak and no harsh solvents
Solvent systemOften ethanol, propylene glycol or high acidWater-rich; ethanol- and PG-free systems demonstrated
Multiple activesOne solubility class per serumHydrophilic + lipophilic in one vehicle
Shelf behaviourActive degrades in solutionVesicle stability 18–26 months reported

Retinoid irritation patterns [7][8]; vehicle tolerability data for a cetosomal versus alcohol-based solution [9].

03 Molecule toggle

Active by active: what changes inside a Cetosome®

Answer first

Each molecule gains something different from entrapment. Hydrophilic actives such as tranexamic acid and niacinamide gain a lipid-compatible carrier. Lipophilic retinoids and ceramides gain oxidation protection and a barrier-like matrix. Irritating acids gain a lower free fraction. Follicular actives gain a solvent-free vehicle. Select a molecule to see the trade-offs.

Molecular weight188.2 Da
logP (approx.)≈ 1.6
Solubility classamphiphilic
Cetosome® residenceLipid lamellae / mantle interface

Normal vehicle

Used at 15–20% as a suspended or partly dissolved acid. High free-acid load contacts the skin all at once.

Problem: Burning, stinging and itching are the most common reasons patients stop azelaic acid.

Cetosome®-entrapped

Partitioned into the vesicle and released as the particles disassemble in the stratum corneum, so less free acid sits on nerve-rich skin at any one moment.[5][6]

Honest limitation: Encapsulation changes tolerability and residence time, not the drug's mechanism. Efficacy endpoints for encapsulated azelaic acid still need head-to-head trials.

04 Test your current routine

Decode your moisturiser or serum

Answer first

Paste the full ingredient list from your current product. The decoder finds tracked actives, flags vehicle stressors such as denatured alcohol, propylene glycol and fragrance allergens, and checks for declared delivery systems. It then explains which actives would most benefit from nanovesicle entrapment. It runs entirely in your browser and stores nothing.

Runs entirely in your browser. Nothing is sent or stored. This is an educational reading of the vehicle, not a medical assessment.

05 Honest clinical limitations

What encapsulation does not do

Answer first

Encapsulation changes delivery, not pharmacology. It cannot make a weak active strong, replace sun protection, or treat disease that needs a prescription. The best controlled data for Cetosome® vehicles come from small, industry-affiliated minoxidil studies, so tolerability benefits for other actives are mechanistically grounded but not yet quantified in randomised trials.

Evidence boundaries

  • Randomised data: one open-label trial, 80 enrolled and 40 analysed; efficacy differences not significant.[9]
  • Real-world data: one retrospective study, no comparator arm.[10]
  • No head-to-head trial yet for cetosomal azelaic acid, retinoids or acids.

When to see a dermatologist

  • Persistent stinging, swelling or rash: possible contact allergy, whatever the vehicle.
  • Active acne, rosacea, melasma or alopecia: diagnosis decides the active; delivery comes second.
  • Pregnancy or breastfeeding: retinoid and other active choices need medical advice.

Want to try a Cetosome® vehicle? These formulations are dispensed through dermatology rather than mass retail. In India, the Monoskin range is the direct route: ask your dermatologist, or start here.

Frequently asked

Is a Cetosome® moisturiser better than a normal moisturiser?

A normal moisturiser hydrates and occludes the surface well. A Cetosome® moisturiser adds lamellar, barrier-like lipid structure and holds actives such as ceramides or niacinamide in vesicles that release gradually, so the benefit lasts longer and is more evenly distributed. For a basic emollient-only product, the difference is smaller.

Do encapsulated serums work better than regular serums?

For irritating or unstable actives such as retinoids, acids and azelaic acid, encapsulation mainly improves stability and tolerability by lowering the early concentration spike. For very gentle actives the gains are incremental. Encapsulation changes delivery, not the pharmacology of the molecule.

Can I tell from the ingredient list whether a product uses Cetosomes®?

Not reliably. Cetyl and cetearyl alcohol are common thickeners in most creams and do not indicate Cetosomes®. Look for an explicit delivery-system claim and ask for particle size, zeta potential and stability data.


References

  1. Feldmann RJ, Maibach HI. Regional Variation in Percutaneous Penetration of 14C Cortisol in Man. Journal of Investigative Dermatology 48(2):181–183. 1967.DOI 10.1038/jid.1967.29
  2. Bos JD, Meinardi MMHM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology 9(3):165–169. 2000.DOI 10.1034/j.1600-0625.2000.009003165.x
  3. Elias PM. Stratum Corneum Defensive Functions: An Integrated View. Journal of Investigative Dermatology 125(2):183–200. 2005.DOI 10.1111/j.0022-202X.2005.23668.x
  4. Barathur RR, Bookout JB (assignee: Cymbiotics, Inc.). Topical dermal delivery compositions using self assembling nanoparticles with cetylated components. US Patent US 9,084,818 B2. 2015.Filed 15 Feb 2013; granted 21 Jul 2015. Claim 1 specifies nanoparticle zeta potential of −20 to −100 mV (or +20 to +100 mV). Measured particle diameters of 60–850 nm; claimed physical dimensions 30 nm–5 µm.
  5. Fitton A, Goa KL. Azelaic Acid: A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. Drugs 41(5):780–798. 1991.DOI 10.2165/00003495-199141050-00007
  6. King S, Campbell J, Rowe R, et al. A systematic review to evaluate the efficacy of azelaic acid in the management of acne, rosacea, melasma and skin aging. Journal of Cosmetic Dermatology 22(10):2650–2662. 2023.DOI 10.1111/jocd.15923
  7. Mukherjee S, Date A, Patravale V, Korting HC, Roeder A, Weindl G. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clinical Interventions in Aging 1(4):327–348. 2006.DOI 10.2147/ciia.2006.1.4.327
  8. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology 74(5):945–973.e33. 2016.DOI 10.1016/j.jaad.2015.12.037
  9. Sattur S, Talathi A, Shetty G, Arsiwala S, Pereira R, Dhoot D. Comparative Clinical Study Evaluating the Efficacy and Safety of Topical 5% Cetosomal Minoxidil and Topical 5% Alcohol-Based Minoxidil Solutions for the Treatment of Androgenetic Alopecia in Indian Men. Cureus 15(10):e46568. 2023.DOI 10.7759/cureus.46568 · PMID 37937040 · PMC10626207Randomised, open-label, 5 centres; 80 enrolled, 40 analysed. One author employed by the product's marketing company.
  10. Kerure A, Ghalla M, Mahajan S, Dhoot D, Barkate H. Real-World Effectiveness, Safety, and Tolerability of Cetosomal Minoxidil 5% Alone and a Fixed Drug Combination of Cetosomal Minoxidil 5% With Finasteride 0.1% in the Management of Androgenetic Alopecia (Inbilt Study). Cureus 15(7):e41681. 2023.DOI 10.7759/cureus.41681 · PMID 37575862 · PMC10413304Retrospective, 66 centres, n = 261. Industry-affiliated authors (employees of the product's marketing company).

Methodology

Content is written from primary sources: granted US patent text, peer-reviewed journals indexed in PubMed or Crossref, and regulator publications. Numerical specifications are quoted exactly as reported in the cited source. Where data are illustrative models rather than measurements, the figure says so.

Conflict of interest & scope

Cetosomes.com is operated in association with parties that manufacture and dispense Cetosome®-based formulations. This site explains vehicle and delivery biophysics; it does not diagnose, treat or prescribe. Clinical decisions belong to a qualified dermatologist or physician. Research articles in the Journal carry no product or brand references.

In your routine or your clinic

Explore Cetosome® formulations

Cetosome® vehicles are dispensed through dermatology, not mass retail. The direct way to bring the technology into your routine or practice is Monoskin, the dermatological range built on the platform.

For your skin: choose a need

For your clinic

Stocking or prescribing Cetosome® formulations? Reach the clinic team, or ask our formulation desk for the literature dossier.

Opens monoskin.com in a new tab. Diagnosis and the choice of active belong to your dermatologist.